Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC β-lactamase

Genetics

Volumn 164, Issue 1, 2003, Pages 23-29

  Barlow, Miriam ^a   Hall, Barry G ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; PIPERACILLIN; PROTEIN CMY 2; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; CITROBACTER FREUNDII; DRUG STRUCTURE; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PRIORITY JOURNAL;

BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; DIRECTED MOLECULAR EVOLUTION; ESCHERICHIA COLI;

CITROBACTER FREUNDII; PROKARYOTA;

EID: 0038192438     PISSN: 00166731     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. AMBLER, R. P., 1980 The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289: 321-331.
2. BARLOW, M., and B. G. HALL, 2002a Origin and evolution of the AmpC β-lactamases of Citrobacter freundii. Antimicrob. Agents Chemother. 46: 1190-1198.
3. BARLOW, M., and B. G. HALL, 2002b Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the TEM β-lactamase. Genetics 160: 823-832.
4. BARLOW, M., and B. G. HALL, 2003 Experimental prediction of the natural evolution of antibiotic resistance. Genetics 163: 1237-1241.
5. BAUERNFEIND, A., Y. CHONG and S. SCHWEIGHART, 1989 Extended broad spectrum beta-lactamase in Klebsiella pneumoniac including resistance to cephamycins. Infection 17: 316-321.
6. BAUERNFEIND, A., S. SCHWEIGART, K. DORNBUSCH and H. GIAMARELLOU, 1990 A transferable cephamycinase in Klebsiella pneumoniae. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC. Abstract 941.
7. CLARKE, P. H., 1984 Amidases of Pseudomonasaeruginosa, pp. 187-231 in Microorganisms as Model Systems for Studying Evolution, edited by R. P. MORTLOCK. Plenum Press, New York/London.
8. HALL, B. G., 1984 The evolved β-galactosidase system of Escherichia coli, pp. 165-185 in Microorganisms as Model Systems for Studying Evolution, edited by R. P. MORTLOCK. Plenum Press, New York/London.
9. HALL, B. G., 1995 Evolutionary potential of the ebgA gene. Mol. Biol. Evol. 12: 514-517.
10. HALL, B. G., 1999a Experimental evolution of Ebg enzyme provides clues about the evolution of catalysis and to evolutionary potential. FEMS Microbiol. Lett. 174: 1-8.
11. HALL, B. G., 1999b Toward an understanding of evolutionary potential. FEMS Microbiol. Lett. 178: 1-6.
12. HALL, B. G., 2001 Predicting evolutionary potential. 1. Predicting the evolution of a lactose-PTS system in Escherichia coli. Mol. Biol. Evol. 18: 1389-1400.
13. HALL, B. G., 2002 Predicting evolution by in vitro evolution requires determining evolutionary pathways. Antimicrob. Agents Chemother. 46: 3035-3038.
14. HALL, B. G., and H. S. MALIK, 1998 Determining the evolutionary potential of a gene. Mol. Biol. Evol. 15: 514-517.
15. KNOX, J. R., 1995 Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39: 2593-2601.
16. LEBLANC, D. J., and R. P. MORTLOCK, 1971 Metabolism of D-arabinose: a new pathway in Escherichia coli. J. Bacteriol. 106: 90-96.
17. MEDEIROS, A. A., 1997 Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin. Infect. Dis. 24: S19-S45.
18. MORTLOCK, R. P. (Editor), 1984 Microorganisms as Model Systems for Studying Evolution. Plenum Press, New York/London.
19. MORTLOCK, R. P., D. D. FOSSIT and W. A. WOOD, 1965 A basis for utilization of unnatural pentoses and pentitols by Aerobacter aerogenes. Proc. Natl. Acad. Sci. USA 54: 572-579.
20. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS, 2001 Performance Standards for Antimicrobial Susceptibility Testing: Supplemental Tables. NCCLS Document M100-S11, National Committee for Clinical Laboratory Standards, Wayne, PA.
21. STEMMER, W. P. C., 1994 Rapid evolution of a protein in vitro by DNA shuffling. Nature 370: 389-390.
22. VAKULENKO, S. B., B. GERYK, L. P. KOTRA, S. MOBASHERY and S. A. LERNER, 1998 Selection and characterization of beta-lactambeta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene. Antimicrob. Agents Chemother. 42: 1542-1548.
23. VAKULENKO, S. B., D. GOLEMI, B. GERYK, M. SUVOROV, J. R. KNOX et al., 2002 Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime. Antimicrob. Agents Chemother. 46: 1966-1970.